Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-2-16
|
pubmed:abstractText |
Although several MAGE-1 peptides have already been identified, the MAGE-1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA-A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-I-restricted manner. By using the MAGE-1/HLA-A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/MAGEA1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Melanoma-Specific Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
18
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
169-72
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9935194-Alleles,
pubmed-meshheading:9935194-Antibodies, Monoclonal,
pubmed-meshheading:9935194-Antibody Specificity,
pubmed-meshheading:9935194-Antigens, Neoplasm,
pubmed-meshheading:9935194-Cell Line,
pubmed-meshheading:9935194-Genetic Code,
pubmed-meshheading:9935194-HLA-A Antigens,
pubmed-meshheading:9935194-Humans,
pubmed-meshheading:9935194-Melanoma-Specific Antigens,
pubmed-meshheading:9935194-Neoplasm Proteins,
pubmed-meshheading:9935194-RNA, Messenger,
pubmed-meshheading:9935194-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:9935194-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:9935194-T-Lymphocytes, Regulatory,
pubmed-meshheading:9935194-Tumor Cells, Cultured
|
pubmed:year |
1999
|
pubmed:articleTitle |
A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.
|
pubmed:affiliation |
Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.
|
pubmed:publicationType |
Journal Article
|